NRG announces £16m Series A for IND for Parkinson’s and ALS
pharmaphorum
NOVEMBER 9, 2022
In ALS , the protein TDP-43 triggers neuroinflammation via activation of the innate immune sensor STING. This novel pathological mechanism is being targeted by NRG and was identified by the company’s collaborator, Professor Seth Masters of Melbourne, Australia’s Walter and Eliza Hall Institute of Medical Research (WEHI).
Let's personalize your content